Michael Burry's Portfolio
MICHAEL BURRY'S SCION ASSET MANAGEMENT Q4 2024 PORTFOLIO
Scion Asset Management, a hedge fund managed by Michael Burry, disclosed 13 security holdings in their SEC 13F filing for the fourth quarter of 2024, with a total portfolio value of $77,435,131
Scion Asset Management Portfolio Analysis
Based on 13F filing for reporting period: Q4, 2024
Portfolio Manager
Michael J. Burry
Filing Date
February 14, 2025
Total Value
$77,435,131
Number of Positions
13
Portfolio Allocation
Holdings Breakdown
| Rank | Company Name | % of Portfolio | Ticker | Shares | Market Value ($) |
|---|
Michael Burry's Portfolio
As of Q4 2024, Michael Burry's portfolio reveals a strategic recalibration, with both reductions in key Chinese tech holdings and new bets in the healthcare and consumer sectors. Below is a detailed overview of his latest positions and notable changes since the previous quarter.
Top Holdings
Additional Holdings
Portfolio Strategy Analysis
Alibaba and JD.com—previously among the largest holdings—were notably trimmed. This pivot indicates a desire to lock in gains or reduce risk exposure amid regulatory headwinds and economic uncertainties in China. Still, both remain top holdings, and Burry offset these cuts by initiating a new position in Pinduoduo.
The portfolio features significant activity in healthcare, with Molina Healthcare partially reduced but HCA Healthcare newly added. Oscar Health further diversifies Burry's bets in the sector. This move suggests a preference for stable, demand-driven businesses to balance out more volatile tech positions.
New positions in Estee Lauder, V.F. Corp., and Canada Goose highlight a tilt toward consumer discretionary and luxury brands. Bruker and Magnera represent specialized bets, possibly capitalizing on niche growth opportunities in diagnostics, scientific research, or emerging markets.
After previously cutting insurance exposure, Burry significantly increased his stake in American Coastal Insurance. This addition could reflect an opportunistic move based on pricing or a reevaluation of risk within the property and casualty segment, potentially taking advantage of market inefficiencies in this sector.
Conclusion
Michael Burry's Q4 2024 portfolio underscores a blend of caution and conviction. While reducing stakes in top Chinese e-commerce names, he has diversified within the tech sector (Baidu, Pinduoduo) and reinforced his defensive positioning through healthcare investments (Molina, HCA, Oscar).
New consumer plays (Estee Lauder, V.F. Corp., Canada Goose) and expanded insurance exposure (American Coastal) reflect opportunistic moves to capture value in sectors poised for recovery or stable returns.
These shifts suggest Burry is balancing risk management—by trimming oversized stakes and emphasizing defensive healthcare—with targeted growth opportunities in consumer, specialty, and Chinese tech segments. As markets evolve, his portfolio positioning highlights a continued willingness to pivot quickly and capitalize on changing market dynamics, all while maintaining core convictions in both tech and healthcare.
Michael Burry's Stocks Performance
Introduction
In his Q4 2024 13F filing, Michael Burry’s Scion Asset Management disclosed 13 positions valued at $77.4 million. From those reported prices to today’s marks (April 29, 2025), outcomes vary widely: Alibaba up +39.60%, Molina Healthcare up +10.02%, while VF Corp. plunged –46.09% and Bruker –32.34%. Below we update each holding’s reported vs. current price performance and explore Burry’s likely rationale given early 2025 market themes.
Q4 2024 Portfolio at a Glance
| Company (Ticker) | Reported Price | Current Price | % Difference |
|---|---|---|---|
| Alibaba (BABA) | $84.79 | $118.37 | +39.60% |
| American Coastal (ACIC) | $13.46 | $11.51 | –14.49% |
| Baidu (BIDU) | $84.31 | $90.37 | +7.19% |
| Bruker (BRKR) | $58.62 | $39.66 | –32.34% |
| Canada Goose (GOOS) | $10.03 | $8.32 | –17.05% |
| Estée Lauder (EL) | $74.98 | $59.14 | –21.13% |
| HCA Healthcare (HCA) | $300.15 | $332.02 | +10.62% |
| JD.com (JD) | $34.67 | $32.70 | –5.68% |
| Magnera (MAGN) | $18.17 | $14.65 | –19.37% |
| Molina Healthcare (MOH) | $291.05 | $320.20 | +10.02% |
| Oscar Health (OSCR) | $13.44 | $12.62 | –6.10% |
| Pinduoduo (PDD) | $96.99 | $103.09 | +6.29% |
| VF Corp. (VFC) | $21.46 | $11.57 | –46.09% |
China Tech Reassessment
Alibaba, JD.com, Baidu & Pinduoduo
Burry’s China tech bets continue to drive performance. Alibaba is up +39.60% on renewed consumer demand and spin-offs. Baidu rose +7.19% thanks to AI progress. Pinduoduo gained +6.29% on strong user metrics. JD.com fell –5.68% amid margin pressures despite operational improvements.
Healthcare & Insurance
Molina Healthcare, HCA Healthcare, Oscar Health & American Coastal
Defensive picks held up well: Molina Healthcare +10.02% on government-backed stability; HCA Healthcare +10.62% via reliable cash flows. Oscar Health dipped –6.10% in profit-taking, while American Coastal fell –14.49% amidst reinsurance cycle headwinds.
Consumer Brands
Estée Lauder, VF Corp. & Canada Goose
Value contrarians took hits: Estée Lauder –21.13% on travel-retail softness; VF Corp. –46.09% amid apparel weakness; Canada Goose –17.05% due to inventory corrections. Long-term brand recovery remains the thesis.
Industry & Science
Bruker & Magnera
Bruker slid –32.34% despite anticipated R&D spending, while Magnera dropped –19.37% post-spinoff. Both remain watchlist candidates for special-situation upside if industrial demand rebounds.
The Big Picture
- Value vs. Growth: Big winners in China tech and healthcare offset steep losses in consumer and industrial names.
- Rate Environment: Favored cash generators and stable franchises amid rising rates.
- Thematic Diversification: Balanced U.S. and China exposure to manage geopolitical and macro risks.
- Defensive Tilt: Insurance and healthcare helped cushion broader market swings.
Conclusion
From reported filing prices through April 29, 2025, Burry’s Q4 2024 portfolio shows standout gains—Alibaba (+39.60%), HCA Healthcare (+10.62%)—and deep drawdowns—VF Corp. (–46.09%), Bruker (–32.34%). His mix of China tech, defensive healthcare, contrarian consumer, and niche industrial plays reflects a multi-scenario, deep-value framework tailored for early 2025’s market headwinds and opportunities.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Please conduct your own research or consult a licensed advisor before making any investment decisions.
